Natural History of Ocular GVHD

目前尚无关于该方案的数据可供报告。 到目前为止，已经招募了20名受试者，第一名参与者在自体干细胞移植后接近两年的检查。 一些患者被建议开始局部使用环孢霉素滴眼液，以应对眼部指标的变化（症状、泪液分泌下降或表面干燥恶化）。 我们的团队希望将患者症状和检查结果的变化与泪液生物标志物的变化相关联。 我们预计在未来一个月内收到我们的非NIH合作者进行的泪膜生物标志物的首次处理结果，并预计在下一个报告期内获得结果摘要。

There are no data yet to report on this protocol. To date, 20 subjects have been enrolled, with the first participant nearing the two-year exam following autologous stem cell transplant. Several patients have been advised to initiate topical cyclosporine eye drops in response to changes in ocular indicators (symptoms, drop in Schirmers tear production, or worsening of surface dryness). Our team hopes to correlate changes in patient symptoms and exam findings with changes in the tear fluid biomarkers. We anticipate receiving the results of the first processing of tear film biomarker, performed by our non-NIH collaborators, in the coming month, and anticipate having a summary of findings by the next reporting period.